5 unknown, 3 completed. 6 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow SKLB1028: new trials by email Literature Review of SKLB1028 trials Research Report on SKLB1028
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SKLB1028 in Patients With Advanced Solid Tumor SKLB1028 - Advanced Solid Tumors | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 98 | 2021-10-01 | 2021-10-11 |
| A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects [14C] SKLB1028 - Healthy Male Subjects | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 6 | 2021-08-06 | 2022-05-11 |
| A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects SKLB1028, Itraconazole, Gemfibrozil - Healthy Subjects | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 42 | 2021-06-07 | 2021-10-06 |
| A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects SKLB1028, Midazolam - Healthy Subjects | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 14 | 2021-06-07 | 2021-10-07 |
| A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects SKLB1028 - Healthy Subjects | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 26 | 2021-04-14 | 2021-11-17 |
| A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated SKLB1028, Salvage Chemotherapy - Acute Myeloid Leukemia (AML) | Phase 3 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 315 | 2021-03-24 | 2021-11-02 |
| A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients SKLB1028 150mg bid, SKLB1028 200mg bid, SKLB1028 300mg qd - Acute Myeloid Leukemia | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 30 | 2019-07-01 | 2019-07-16 |
| A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia SKLB1028 - Acute Myeloid Leukemia | Phase 1 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 18 | 2016-05-01 | 2016-08-09 |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (8)
China (8)
Suxia Luo, Master (1) · Ting Liu, Dr. (1)